{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:36:59Z","timestamp":1794263819994,"version":"4.9.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010890","name":"Chinese Government Scholarship","doi-asserted-by":"publisher","award":["201907000127"],"award-info":[{"award-number":["201907000127"]}],"id":[{"id":"10.13039\/501100010890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 inhibition in the kidney) and off-target effects that likely both contribute to the reported cardiovascular benefit. Here we review the literature on direct effects of SGLT2is on various cardiac cells and derive at an unifying working hypothesis. SGLT2is acutely and directly (1) inhibit cardiac sodium transporters and alter ion homeostasis, (2) reduce inflammation and oxidative stress, (3) influence metabolism, and (4) improve cardiac function. We postulate that cardiac benefit modulated by SGLT2i\u2019s can be commonly attributed to their inhibition of sodium-loaders in the plasma membrane (NHE-1, Nav1.5, SGLT) affecting intracellular sodium-homeostasis (the sodium-interactome), thereby providing a unifying view on the various effects reported in separate studies. The SGLT2is effects are most apparent when cells or hearts are subjected to pathological conditions (reactive oxygen species, inflammation, acidosis, hypoxia, high saturated fatty acids, hypertension, hyperglycemia, and heart failure sympathetic stimulation) that are known to prime these plasmalemmal sodium-loaders. In conclusion, the cardiac sodium-interactome provides a unifying testable working hypothesis and a possible, at least partly, explanation to the clinical benefits of SGLT2is observed in the diseased patient.<\/jats:p>","DOI":"10.1186\/s12933-022-01480-1","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T16:14:31Z","timestamp":1647620071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":171,"title":["Direct cardiac effects of SGLT2 inhibitors"],"prefix":"10.1186","volume":"21","author":[{"given":"Sha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"Hollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coert J.","family":"Zuurbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"10254","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/s0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(20)31824-9.","journal-title":"Lancet"},{"issue":"10166","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(18)32590-x","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(18)32590-x.","journal-title":"Lancet"},{"issue":"21","key":"1480_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"3","key":"1480_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373. https:\/\/doi.org\/10.1007\/s00125-016-4134-x.","journal-title":"Diabetologia"},{"issue":"1\u20132","key":"1480_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11010-014-2262-5","volume":"400","author":"NN Hamouda","year":"2015","unstructured":"Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2015;400(1\u20132):57\u201368. https:\/\/doi.org\/10.1007\/s11010-014-2262-5.","journal-title":"Mol Cell Biochem"},{"key":"1480_CR6","doi-asserted-by":"publisher","first-page":"41166","DOI":"10.1038\/srep41166","volume":"7","author":"A Van Steenbergen","year":"2017","unstructured":"Van Steenbergen A, Balteau M, Ginion A, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 2017;7:41166. https:\/\/doi.org\/10.1038\/srep41166.","journal-title":"Sci Rep"},{"key":"1480_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575. https:\/\/doi.org\/10.3389\/fphys.2018.01575.","journal-title":"Front Physiol"},{"issue":"4","key":"1480_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (sglt2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.004.","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"1480_CR10","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00136.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1480_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722\u20136. https:\/\/doi.org\/10.1007\/s00125-017-4509-7.","journal-title":"Diabetologia"},{"issue":"4","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, Lucht CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642\u20138. https:\/\/doi.org\/10.1002\/ehf2.12336.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"1480_CR13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690\u2013700. https:\/\/doi.org\/10.1002\/ejhf.1328.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, et al. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188\u2013204. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053350.","journal-title":"Circulation"},{"issue":"1","key":"1480_CR15","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/circheartfailure.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced nlrp3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1):e006277. https:\/\/doi.org\/10.1161\/circheartfailure.119.006277.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1480_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y.","journal-title":"Cardiovasc Diabetol"},{"key":"1480_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104781","volume":"157","author":"D Cappetta","year":"2020","unstructured":"Cappetta D, De Angelis A, Ciuffreda LP, et al. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res. 2020;157: 104781. https:\/\/doi.org\/10.1016\/j.phrs.2020.104781.","journal-title":"Pharmacol Res"},{"issue":"12","key":"1480_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00109-020-01989-6","volume":"98","author":"S Pabel","year":"2020","unstructured":"Pabel S, Reetz F, Dybkova N, et al. Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes. J Mol Med (Berl). 2020;98(12):1689\u2013700. https:\/\/doi.org\/10.1007\/s00109-020-01989-6.","journal-title":"J Mol Med (Berl)"},{"key":"1480_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13024","author":"M Trum","year":"2020","unstructured":"Trum M, Riechel J, Lebek S, et al. Empagliflozin inhibits Na(+)\/H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020. https:\/\/doi.org\/10.1002\/ehf2.13024.","journal-title":"ESC Heart Fail"},{"key":"1480_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa323","author":"YJ Chung","year":"2020","unstructured":"Chung YJ, Park KC, Tokar S, et al. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2020. https:\/\/doi.org\/10.1093\/cvr\/cvaa323.","journal-title":"Cardiovasc Res"},{"key":"1480_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab129","author":"CJ Zuurbier","year":"2021","unstructured":"Zuurbier CJ, Baartscheer A, Schumacher CA, Fiolet JWT, Coronel R. SGLT2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions. Cardiovasc Res. 2021. https:\/\/doi.org\/10.1093\/cvr\/cvab129.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"1480_CR22","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","volume":"115","author":"L Uthman","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O, et al. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res. 2019;115(10):1533\u201345. https:\/\/doi.org\/10.1093\/cvr\/cvz004.","journal-title":"Cardiovasc Res"},{"key":"1480_CR23","doi-asserted-by":"publisher","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","volume":"146","author":"L Uthman","year":"2022","unstructured":"Uthman L, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells. Biomed Pharmacother. 2022;146:112515. https:\/\/doi.org\/10.1016\/j.biopha.2021.112515.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1480_CR24","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.3390\/ijms22116044","volume":"22","author":"X Li","year":"2021","unstructured":"Li X, Romer G, Kerindongo RP, et al. Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species. Int J Mol Sci. 2021;22(11):6044. https:\/\/doi.org\/10.3390\/ijms22116044.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553\u20138. https:\/\/doi.org\/10.1007\/s10557-018-6837-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1480_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C, et al. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol. 2020;19(1):46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5.","journal-title":"Cardiovasc Diabetol"},{"key":"1480_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114276","volume":"182","author":"CH Lescano","year":"2020","unstructured":"Lescano CH, Leonardi G, Torres PHP, et al. The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. Biochem Pharmacol. 2020;182: 114276. https:\/\/doi.org\/10.1016\/j.bcp.2020.114276.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1480_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1515\/hsz-2013-0241","volume":"395","author":"J Lugrin","year":"2014","unstructured":"Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203\u201330. https:\/\/doi.org\/10.1515\/hsz-2013-0241.","journal-title":"Biol Chem"},{"issue":"7","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/ars.2012.5149","volume":"20","author":"M Mittal","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126\u201367. https:\/\/doi.org\/10.1089\/ars.2012.5149.","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"1480_CR30","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/01.cir.0000055318.09997.1f","volume":"107","author":"N Suematsu","year":"2003","unstructured":"Suematsu N, Tsutsui H, Wen J, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 2003;107(10):1418\u201323. https:\/\/doi.org\/10.1161\/01.cir.0000055318.09997.1f.","journal-title":"Circulation"},{"issue":"6","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","volume":"69","author":"X Sun","year":"2020","unstructured":"Sun X, Han F, Lu Q, et al. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 2020;69(6):1292\u2013305. https:\/\/doi.org\/10.2337\/db19-0991.","journal-title":"Diabetes"},{"key":"1480_CR32","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.mce.2019.110642","volume":"501","author":"Q Lu","year":"2020","unstructured":"Lu Q, Liu J, Li X, et al. Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway. Mol Cell Endocrinol. 2020;501:110642. https:\/\/doi.org\/10.1016\/j.mce.2019.110642.","journal-title":"Mol Cell Endocrinol"},{"key":"1480_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"CN Koyani","year":"2020","unstructured":"Koyani CN, Plastira I, Sourij H, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020;158: 104870. https:\/\/doi.org\/10.1016\/j.phrs.2020.104870.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1480_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation. Cardiovasc Res. 2021;117(2):495\u2013507. https:\/\/doi.org\/10.1093\/cvr\/cvaa123.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"1480_CR35","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.3390\/ijms22115437","volume":"22","author":"J Goerg","year":"2021","unstructured":"Goerg J, Sommerfeld M, Greiner B, et al. Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a. Int J Mol Sci. 2021;22(11):5437. https:\/\/doi.org\/10.3390\/ijms22115437.","journal-title":"Int J Mol Sci"},{"key":"1480_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab420","author":"H Kondo","year":"2021","unstructured":"Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab420.","journal-title":"Eur Heart J"},{"issue":"1","key":"1480_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1479164117733626","volume":"15","author":"T Gaspari","year":"2018","unstructured":"Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64\u201373. https:\/\/doi.org\/10.1177\/1479164117733626.","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"1480_CR38","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","volume":"8","author":"SJ Mancini","year":"2018","unstructured":"Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018;8(1):5276. https:\/\/doi.org\/10.1038\/s41598-018-23420-4.","journal-title":"Sci Rep"},{"issue":"3","key":"1480_CR39","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/jcmm.14233","volume":"24","author":"S Khemais-Benkhiat","year":"2020","unstructured":"Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, et al. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med. 2020;24(3):2109\u201322. https:\/\/doi.org\/10.1111\/jcmm.14233.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"1480_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M, et al. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci. 2019;4(5):575\u201391. https:\/\/doi.org\/10.1016\/j.jacbts.2019.04.003.","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"1480_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","volume":"99","author":"RP Juni","year":"2021","unstructured":"Juni RP, Al-Shama R, Kuster DWD, et al. Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney Int. 2021;99(5):1088\u2013101. https:\/\/doi.org\/10.1016\/j.kint.2020.12.013.","journal-title":"Kidney Int"},{"issue":"8","key":"1480_CR42","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","volume":"39","author":"R Ortega","year":"2019","unstructured":"Ortega R, Collado A, Selles F, et al. SGLT-2 (sodium-glucose cotransporter 2) inhibition reduces Ang II (Angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (Apolipoprotein E) knockout mice. Arterioscler Thromb Vasc Biol. 2019;39(8):1614\u201328. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312659.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1480_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman L, Homayr A, Juni RP, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor alpha-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem. 2019;53(5):865\u201386. https:\/\/doi.org\/10.33594\/000000178.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"1480_CR44","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/ars.2019.7923","volume":"34","author":"PE Nikolaou","year":"2021","unstructured":"Nikolaou PE, Efentakis P, Abu Qourah F, et al. Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid Redox Signal. 2021;34(7):551\u201371. https:\/\/doi.org\/10.1089\/ars.2019.7923.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1480_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","volume":"20","author":"SH Park","year":"2021","unstructured":"Park SH, Belcastro E, Hasan H, et al. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins. Cardiovasc Diabetol. 2021;20(1):65. https:\/\/doi.org\/10.1186\/s12933-021-01252-3.","journal-title":"Cardiovasc Diabetol"},{"key":"1480_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109825","volume":"77","author":"S Sukhanov","year":"2021","unstructured":"Sukhanov S, Higashi Y, Yoshida T, et al. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1beta and IL-18 secretion. Cell Signal. 2021;77: 109825. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109825.","journal-title":"Cell Signal"},{"issue":"2","key":"1480_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119\u201332. https:\/\/doi.org\/10.1007\/s10557-017-6725-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"1480_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s00125-019-4819-z","volume":"62","author":"J Mustroph","year":"2019","unstructured":"Mustroph J, Lucht CM, Wagemann O, et al. Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1. Diabetologia. 2019;62(4):726\u20139. https:\/\/doi.org\/10.1007\/s00125-019-4819-z.","journal-title":"Diabetologia"},{"key":"1480_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.592233","volume":"7","author":"H Zhang","year":"2020","unstructured":"Zhang H, Uthman L, Bakker D, et al. Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases alpha-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts. Front Cardiovasc Med. 2020;7: 592233. https:\/\/doi.org\/10.3389\/fcvm.2020.592233.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1480_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","volume":"114","author":"HE Baker","year":"2019","unstructured":"Baker HE, Kiel AM, Luebbe ST, et al. Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol. 2019;114(3):25. https:\/\/doi.org\/10.1007\/s00395-019-0733-2.","journal-title":"Basic Res Cardiol"},{"key":"1480_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119440","volume":"276","author":"MA Azam","year":"2021","unstructured":"Azam MA, Chakraborty P, Si D, et al. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci. 2021;276: 119440. https:\/\/doi.org\/10.1016\/j.lfs.2021.119440.","journal-title":"Life Sci"},{"issue":"1","key":"1480_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20(1):236. https:\/\/doi.org\/10.1186\/s12933-021-01430-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1480_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12933-021-01400-9","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Cardiovasc Diabetol. 2021;20(1):205. https:\/\/doi.org\/10.1186\/s12933-021-01400-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1480_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https:\/\/doi.org\/10.1186\/s12933-021-01366-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1480_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","volume":"23","author":"A Kaplan","year":"2018","unstructured":"Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev. 2018;23(3):419\u201337. https:\/\/doi.org\/10.1007\/s10741-017-9665-9.","journal-title":"Heart Fail Rev"},{"issue":"21","key":"1480_CR56","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/ijms21217833","volume":"21","author":"YC Hou","year":"2020","unstructured":"Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci. 2020;21(21):7833. https:\/\/doi.org\/10.3390\/ijms21217833.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1480_CR57","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1161\/01.cir.0000016701.85760.97","volume":"105","author":"S Despa","year":"2002","unstructured":"Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM. Intracellular Na(+) concentration is elevated in heart failure but Na\/K pump function is unchanged. Circulation. 2002;105(21):2543\u20138. https:\/\/doi.org\/10.1161\/01.cir.0000016701.85760.97.","journal-title":"Circulation"},{"issue":"4","key":"1480_CR58","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/s0008-6363(02)00735-6","volume":"57","author":"SM Pogwizd","year":"2003","unstructured":"Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res. 2003;57(4):887\u201396. https:\/\/doi.org\/10.1016\/s0008-6363(02)00735-6.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"1480_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/01.cir.0000023042.50192.f4","volume":"106","author":"B Pieske","year":"2002","unstructured":"Pieske B, Maier LS, Piacentino V 3rd, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002;106(4):447\u201353. https:\/\/doi.org\/10.1161\/01.cir.0000023042.50192.f4.","journal-title":"Circulation"},{"issue":"4","key":"1480_CR60","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/s0008-6363(02)00809-x","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Fiolet JW. Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003;57(4):1015\u201324. https:\/\/doi.org\/10.1016\/s0008-6363(02)00809-x.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"1480_CR61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9): e002183. https:\/\/doi.org\/10.1161\/JAHA.115.002183.","journal-title":"J Am Heart Assoc"},{"key":"1480_CR62","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3389\/fphys.2018.01473","volume":"9","author":"NM Doliba","year":"2018","unstructured":"Doliba NM, Babsky AM, Osbakken MD. The role of sodium in diabetic cardiomyopathy. Front Physiol. 2018;9:1473. https:\/\/doi.org\/10.3389\/fphys.2018.01473.","journal-title":"Front Physiol"},{"issue":"7828","key":"1480_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41586-020-2551-y","volume":"586","author":"P Hernansanz-Agustin","year":"2020","unstructured":"Hernansanz-Agustin P, Choya-Foces C, Carregal-Romero S, et al. Na(+) controls hypoxic signalling by the mitochondrial respiratory chain. Nature. 2020;586(7828):287\u201391. https:\/\/doi.org\/10.1038\/s41586-020-2551-y.","journal-title":"Nature"},{"issue":"10","key":"1480_CR64","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCRESAHA.118.310082","volume":"122","author":"E Bertero","year":"2018","unstructured":"Bertero E, Maack C. Calcium signaling and reactive oxygen species in mitochondria. Circ Res. 2018;122(10):1460\u201378. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.310082.","journal-title":"Circ Res"},{"issue":"1","key":"1480_CR65","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/s41467-020-18160-x","volume":"11","author":"D Aksentijevic","year":"2020","unstructured":"Aksentijevic D, Karlstaedt A, Basalay MV, et al. Intracellular sodium elevation reprograms cardiac metabolism. Nat Commun. 2020;11(1):4337. https:\/\/doi.org\/10.1038\/s41467-020-18160-x.","journal-title":"Nat Commun"},{"issue":"14","key":"1480_CR66","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1074\/jbc.RA119.011902","volume":"295","author":"M Szibor","year":"2020","unstructured":"Szibor M, Gizatullina Z, Gainutdinov T, et al. Cytosolic, but not matrix, calcium is essential for adjustment of mitochondrial pyruvate supply. J Biol Chem. 2020;295(14):4383\u201397. https:\/\/doi.org\/10.1074\/jbc.RA119.011902.","journal-title":"J Biol Chem"},{"issue":"7","key":"1480_CR67","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCRESAHA.110.232306","volume":"108","author":"DF Dai","year":"2011","unstructured":"Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108(7):837\u201346. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.232306.","journal-title":"Circ Res"},{"issue":"48","key":"1480_CR68","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","volume":"39","author":"C Maack","year":"2018","unstructured":"Maack C, Lehrke M, Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehy596.","journal-title":"Eur Heart J"},{"issue":"10","key":"1480_CR69","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128(10):1487\u2013513. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318241.","journal-title":"Circ Res"},{"issue":"7","key":"1480_CR70","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/01.cir.99.7.942","volume":"99","author":"Y Murakami","year":"1999","unstructured":"Murakami Y, Zhang Y, Cho YK, et al. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Circulation. 1999;99(7):942\u20138. https:\/\/doi.org\/10.1161\/01.cir.99.7.942.","journal-title":"Circulation"},{"key":"1480_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12931-015-0178-6","volume":"16","author":"GM Balestra","year":"2015","unstructured":"Balestra GM, Mik EG, Eerbeek O, Specht PA, van der Laarse WJ, Zuurbier CJ. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure? Respir Res. 2015;16:6. https:\/\/doi.org\/10.1186\/s12931-015-0178-6.","journal-title":"Respir Res"},{"issue":"3","key":"1480_CR72","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/s0008-6363(98)00332-0","volume":"42","author":"RJ Bache","year":"1999","unstructured":"Bache RJ, Zhang J, Murakami Y, et al. Myocardial oxygenation at high workstates in hearts with left ventricular hypertrophy. Cardiovasc Res. 1999;42(3):616\u201326. https:\/\/doi.org\/10.1016\/s0008-6363(98)00332-0.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1480_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0092-8674(00)81573-1","volume":"93","author":"JD Molkentin","year":"1998","unstructured":"Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215\u201328. https:\/\/doi.org\/10.1016\/s0092-8674(00)81573-1.","journal-title":"Cell"},{"key":"1480_CR74","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.redox.2015.08.010","volume":"6","author":"A Gorlach","year":"2015","unstructured":"Gorlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: a mutual interplay. Redox Biol. 2015;6:260\u201371. https:\/\/doi.org\/10.1016\/j.redox.2015.08.010.","journal-title":"Redox Biol"},{"issue":"7","key":"1480_CR75","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/cvr\/cvy304","volume":"115","author":"CJ Zuurbier","year":"2019","unstructured":"Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, et al. Innate immunity as a target for acute cardioprotection. Cardiovasc Res. 2019;115(7):1131\u201342. https:\/\/doi.org\/10.1093\/cvr\/cvy304.","journal-title":"Cardiovasc Res"},{"issue":"Pt 3","key":"1480_CR76","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1113\/jphysiol.1997.sp022048","volume":"500","author":"CA Ward","year":"1997","unstructured":"Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. 1997;500(Pt 3):631\u201342. https:\/\/doi.org\/10.1113\/jphysiol.1997.sp022048.","journal-title":"J Physiol"},{"issue":"5","key":"1480_CR77","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1161\/CIRCRESAHA.110.221911","volume":"108","author":"S Wagner","year":"2011","unstructured":"Wagner S, Ruff HM, Weber SL, et al. Reactive oxygen species-activated Ca\/calmodulin kinase IIdelta is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res. 2011;108(5):555\u201365. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.221911.","journal-title":"Circ Res"},{"issue":"1","key":"1480_CR78","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2009.12.007","volume":"49","author":"M Vila-Petroff","year":"2010","unstructured":"Vila-Petroff M, Mundina-Weilenmann C, Lezcano N, et al. Ca(2+)\/calmodulin-dependent protein kinase II contributes to intracellular pH recovery from acidosis via Na(+)\/H(+) exchanger activation. J Mol Cell Cardiol. 2010;49(1):106\u201312. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.12.007.","journal-title":"J Mol Cell Cardiol"},{"key":"1480_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07311-x","author":"X Peng","year":"2022","unstructured":"Peng X, Li L, Lin R, et al. Empagliflozin ameliorates ouabain-induced Na(+) and Ca(2+) dysregulations in ventricular myocytes in an Na(+)-dependent manner. Cardiovasc Drugs Ther. 2022. https:\/\/doi.org\/10.1007\/s10557-021-07311-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1480_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00885-8","author":"K Lin","year":"2022","unstructured":"Lin K, Yang N, Luo W, et al. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling. Acta Pharmacol Sin. 2022. https:\/\/doi.org\/10.1038\/s41401-022-00885-8.","journal-title":"Acta Pharmacol Sin"},{"key":"1480_CR81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365","author":"K Katsurada","year":"2021","unstructured":"Katsurada K, Nandi SS, Sharma NM, Patel KP. Enhanced expression and function of renal SGLT2 (sodium-glucose cotransporter 2) in heart failure: role of renal nerves. Circ Heart Fail. 2021. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008365.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"1480_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4070\/kcj.2020.0303","volume":"51","author":"SY Lee","year":"2021","unstructured":"Lee SY, Lee TW, Park GT, et al. Sodium\/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction. Korean Circ J. 2021;51(3):251\u201362. https:\/\/doi.org\/10.4070\/kcj.2020.0303.","journal-title":"Korean Circ J"},{"issue":"3","key":"1480_CR83","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cmet.2021.01.014","volume":"33","author":"N Kosaisawe","year":"2021","unstructured":"Kosaisawe N, Sparta B, Pargett M, Teragawa CK, Albeck JG. Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells. Cell Metab. 2021;33(3):649-665e8. https:\/\/doi.org\/10.1016\/j.cmet.2021.01.014.","journal-title":"Cell Metab"},{"issue":"11","key":"1480_CR84","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1161\/circresaha.121.318982","volume":"129","author":"SE Basehore","year":"2021","unstructured":"Basehore SE, Bohlman S, Weber C, et al. Laminar flow on endothelial cells suppresses eNOS O-GlcNAcylation to promote eNOS activity. Circ Res. 2021;129(11):1054\u201366. https:\/\/doi.org\/10.1161\/circresaha.121.318982.","journal-title":"Circ Res"},{"issue":"12","key":"1480_CR85","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1006\/jmcc.1997.0567","volume":"29","author":"A Baartscheer","year":"1997","unstructured":"Baartscheer A, Schumacher CA, Fiolet JW. Small changes of cytosolic sodium in rat ventricular myocytes measured with SBFI in emission ratio mode. J Mol Cell Cardiol. 1997;29(12):3375\u201383. https:\/\/doi.org\/10.1006\/jmcc.1997.0567.","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"1480_CR86","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360. https:\/\/doi.org\/10.1038\/s41591-021-01536-x.","journal-title":"Nat Med"},{"issue":"4","key":"1480_CR87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713\u201322. https:\/\/doi.org\/10.1002\/ejhf.1713.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1480_CR88","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520\u20136. https:\/\/doi.org\/10.1038\/clpt.2008.251.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1480_CR89","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3109\/00498254.2014.999141","volume":"45","author":"LZ Chen","year":"2015","unstructured":"Chen LZ, Jungnik A, Mao Y, et al. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica. 2015;45(6):520\u20139. https:\/\/doi.org\/10.3109\/00498254.2014.999141.","journal-title":"Xenobiotica"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01480-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01480-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T04:35:43Z","timestamp":1647664543000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01480-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01480-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.J.Z received a research Grant from Boehringer Ingelheim exploring SGLT2i\u2019s mechanisms in murine heart failure models.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}